Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Other 4Thoracic 3Other solid neoplasm 3Lymphoid 3Tumor-Agnostic 2Other neoplasm 2Gynecologic 2Plasma cell 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Anxiety Disorders 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mindfulness-Based Stress Reduction × Dermatologic × Clear all
NCT03174808 2019-11-27

Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)

Yale University

Phase NA Terminated
3 enrolled
DermatologicLymphoid

Anxiety Disorders, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡